CHUGAI PHARMACEUTIC-UNSP ADR Business Summary

Chugai Pharmaceutical Co., Ltd. (CHGCY) operates a research-driven business model centered on a strategic alliance with the Roche Group, which holds a majority stake while allowing Chugai to maintain managerial autonomy. The company generates revenue through three primary streams: domestic sales of in-licensed Roche products, global exports of its proprietary innovations, and significant royalty and milestone income from out-licensed assets like Hemlibra, NEMLUVIO (nemolizumab), and Foundayo (orforglipron). Its business is bifurcated into Oncology and Specialty segments, leveraging world-leading proprietary antibody engineering and macrocyclic peptide technologies to address unmet medical needs. Within the Japanese market, Chugai maintains a dominant position, frequently ranking first in domestic prescription drug sales, where it competes directly with Takeda Pharmaceutical, Astellas Pharma, and Daiichi Sankyo by focusing on high-margin, first-in-class biologics rather than diversified generic portfolios. Leadership is currently spearheaded by Representative Director, President, and CEO Dr. Osamu Okuda, a company veteran who joined in 1987 and previously served as President of Roche Products (Ireland). The executive team includes Director and CFO Iwaaki Taniguchi, who brought extensive financial expertise from Takeda and Recruit Holdings upon joining in 2022, and Executive Vice President Dr. Hitoshi Iikura, who oversees corporate planning and previously led the R&D division. The company was founded in 1925 by Juzo Ueno and has evolved from a local manufacturer into a global biotech powerhouse. Its board is characterized by a mix of internal experts and outside directors, with F. Hoffmann-La Roche Ltd. serving as the anchor investor, providing a stable capital base and a global distribution network that underpins Chugai's "TOP I 2030" growth strategy.